Where there be Patent-Free Markets: Swiss-Swedish Biosimilar for Blindess Reaches Iran

18/01/2016 - 2 minutes

Helvetic BioPharma (Switzerland) estimates that 70,000 people suffer from age-related macular degeneration in Iran, the leading cause of blindness. This deal with Xbrane in Stockholm (Sweden) will debut a biosimilar therapy that could really tackle this problem.

macular_degeneration_vgef_xbrane_helvetic_primm_pharma_lucentis_xlucane_iran_biosimilarXbrane itself is a Swedish biopharma with links to Italy (after an acquisition of the Italian Primm Pharma in October). The company focus is developing its patented protein production using E.coli to produce biosimilars with superior efficiency. It also investigates and develops biodegradable polymer ‘microspheres’ for more controlled release of these drugs.

Xlucane is Xbrane’s biosimilar version of Lucentis (which contains the active substance Ranibizumab) and is used primarily for the treatment of the wet form of age-related macular degeneration (AMD), an eye disease that leads to impaired vision, and in worst case blindness.

Patents for Lucentis in the US and EU expire 2020 and 2022 respectively, while the drug lacks patent protection in many emerging markets, including Iran. However, the world’s first Ranibizumab biosimilar  was actually recently introduced by Intas Pharmaceuticals in India (read our review on the ‘Battle of Biosimilars’

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member